Clinical trial

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904 · Northwestern University, Other · Completed

Key facts

NCT number NCT00004904
Title Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Official title Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 "Veto" Cells
Lead sponsor Northwestern University, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Intervention type Biological, Drug, Procedure
Interventions anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Start date Oct 1, 1999
Primary completion Jul 1, 2000
Completion Jul 1, 2000
First posted Mar 3, 2004
Last update posted Jun 4, 2012
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies